Abstract
The Symposium on Hidradenitis Suppurativa Advances (SHSA) is a joint meeting of the United States Hidradenitis Suppurativa Foundation (HSF) and the Canadian Hidradenitis Suppurativa Foundation (CHSF).This annual cross-disciplinary meeting brings together experts from around the world in an opportunity to discuss the most recent advances in the study of hidradenitis suppurativa (HS).The fifth annual meeting was held virtually on 9-11 October 2020. A record 347 attendees, including 79 people with HS, from 20 different countries attended. Key take-home points included: Clinicians can optimize each visit by listening, provide education, and discuss treatments; a patient decision aid for HS (HS-PDA) is a freely available tool (www.informed-decisions.org); COVID-19 severity in HS patients was not different for patients treated with/without a biologic; comorbidity screening recommendations will be published soon; neutrophil extracellular traps (NETs) may play a role in HS; Do memory Not B cells,T Copy helper 1 cytokines, and interleukin 1 signaling contributes to HS and pathogenesis brodalumab; and and HS-specific are targets for outcome new therapies; measures Penalties novel have therapies emerged are toApply better showing monitor promise disease including severity, a new flare, JAK1 and inhibitor progression (INCB054707) including a patient reported measure (HiSQOL) and an HS-specific investigator global assessment.
Original language | English (US) |
---|---|
Pages (from-to) | 868-873 |
Number of pages | 6 |
Journal | Journal of Drugs in Dermatology |
Volume | 20 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2021 |
All Science Journal Classification (ASJC) codes
- General Medicine